The CE mark was given to Systagenix’s (London, UK) WOUNDCHEK™ Protease Status, the world’s first rapid, point-of-care diagnostic test developed specifically for chronic wounds. The test enables early, targeted intervention and cost-effective use of advanced therapies designed to modulate protease activity. It will be introduced initially across Europe, South Africa, and the Middle East. The first commercial shipment of the kits has commenced.

  Developed by Systagenix Wound Management in collaboration with Alere, and designed to form part of routine wound assessment, WOUNDCHEK Protease Status is easy to use and provides results in just 15 minutes at the point of care. This enables the test to influence treatment decisions immediately and help clinicians target advanced wound care therapies more effectively by identifying when elevated protease activity exists in chronic wounds.

  As the implementation of point-of-care testing is new to many wound care clinicians, Systagenix is investing heavily in training prospective users and is pleased to introduce a new online training tool.

  Visit www.systagenix.com for more information.